Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q3 2024 earnings summary

Executive summary

• Achieved a turnaround in free cash generation, with R$20.3 million generated in Q3 2024 after prior quarters of cash consumption, driven by improved collections and disciplined capex.

• Largest private oncology provider in Brazil, operating 144 units in 40 cities with over 2,900 oncology specialists and ~682,000 treatments in the last twelve months.

• Strategic focus shifted to cash generation and operational efficiency, including restructuring and unification of redundant units.

Financial highlights

• Gross revenue reached R$1.7 billion in Q3 2024, up 12.9% year-over-year; net revenue was R$1.6 billion, up 16.6% year-over-year and 4.3% sequentially.

• Number of procedures increased by 7.9% year-over-year, reaching 150,000 in Q3 2024; average ticket grew 4.9% year-over-year.

• Adjusted EBITDA was R$309.0 million in Q3 2024, up 8.3% year-over-year, with margin at 18.9%.

• Net profit (ex-LTIP/PILP) was R$8.9 million, affected by lower operating leverage and higher expenses.

• Free cash flow for Q3 was R$207.3 million, driven by improved receipts and working capital.

Outlook and guidance

• Guidance for leverage at 2.7x net debt/EBITDA by year-end is maintained, supported by organic cash generation and a strong cash position.

• Management expects PCLD to normalize to historical levels (2%-2.5%) in future quarters, after a temporary low of 0.5% in Q3.

• Focus remains on cash generation, even if it results in temporarily lower margins or slower growth.